This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten
- Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis
- An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector
- Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
- Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
- Optimizing Bispecific Antibody Pretargeting for Use in Radioimmunotherapy
- Pharmacokinetics and Dosimetry Studies for Optimization of Anti-Carcinoembryonic Antigen x Anti-Hapten Bispecific Antibody-mediated Pretargeting of Iodine-131-labeled Hapten in a Phase I Radioimmunotherapy Trial
- In Vivo Evaluation of Pretargeted 64Cu for Tumor Imaging and Therapy
- Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
- A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody
- Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies
- Enhanced Antitumor Activity of Combined Pretargeted Radioimmunotherapy and Paclitaxel in Medullary Thyroid Cancer Xenograft
- Two-Step Targeting of Xenografted Colon Carcinoma Using a Bispecific Antibody and 188Re-Labeled Bivalent Hapten: Biodistribution and Dosimetry Studies
- Pretargeting of Renal Cell Carcinoma: Improved Tumor Targeting with a Bivalent Chelate